US20030059440A1 - Composition and method for moisturizing nasal tissue - Google Patents
Composition and method for moisturizing nasal tissue Download PDFInfo
- Publication number
- US20030059440A1 US20030059440A1 US10/243,637 US24363702A US2003059440A1 US 20030059440 A1 US20030059440 A1 US 20030059440A1 US 24363702 A US24363702 A US 24363702A US 2003059440 A1 US2003059440 A1 US 2003059440A1
- Authority
- US
- United States
- Prior art keywords
- composition
- moisturizing
- nasal
- group
- material selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Definitions
- the present invention generally relates to a method and composition for moisturizing nasal tissue.
- Compounds suitable for moisturizing a nasal cavity or a portion of a nasal cavity are desirable for several reasons.
- application of a moisturizer to the nasal cavity may facilitate and/or promote healthy function of the cavity, which in turn may reduce the duration of symptoms associated with, for example, a common cold or the flu, and which may reduce the likelihood of an infection in the nasal region.
- the nasal cavity performs several functions.
- the lower portion of the cavity includes the nasal epithelium, which is an essential part of the respiratory tract.
- the nasal epithelium is very vascular, which allows the epithelium to warm inspired air.
- the epithelium is also relatively moist, which allows it to moisten and cleanse inspired air.
- the cavity also includes a mucous membrane which lines the nasal cavity and traps fine particles such as dust, pollen and smoke.
- Nasal epithelial cells play an important role in warding of both bacteria and viruses.
- the cells act as a chemical, mechanical and microbiological barrier to infection.
- small glands within the nose secrete mucus, onto the nasal epithelial cells to moisten a portion of the nasal membrane.
- the cilia hair like structures implanted in the epithelium and the immune system's first line of defense, are the cells responsible for trapping dust and bacteria. When the nasal membrane becomes dry, the cilia's movement slows and bacteria are better able to enter the respiratory system.
- the epithelial cells must generally be healthy and moist.
- Sinusitis and allergens are two common conditions that affect the proper functioning of the nasal membrane.
- Sinusitis is an infection of any of the four groups of sinuses that prevents the proper drainage of mucous in the sinus passages.
- Sinusitis may stem from a cold or flu, allergies, pollution, injuries or various other conditions, which often result in a dry nasal passage.
- Inhaled allergens including dust, pollen, molds, animal dander, and grass may react with the mucous membrane. This reaction may result in a drying or irritation of the nasal cavity. These factors along with dry climates, changing seasons, and pollution can all lead to nasal cavity dryness which may cause cracking and bleeding of the nose as well as various other acute or chronic conditions. Accordingly, methods and compositions for moisturizing a nasal membrane are desired.
- the present invention provides improved methods and compositions for moisturizing the nasal membrane.
- the present invention provides an effective nasal moisturizer that does not irritate nasal epithelium.
- the nasal moisturizer is a composition that includes an active moisturizing ingredient within a viscous gel.
- the gel has a viscosity in the range of 2,500 to 40,000 centipoise, preferably in the range of 5,000 to 20,000 centipoise.
- the active ingredient may include any number of materials appropriate for moisturizing nasal tissue.
- the nasal moisturizer is configured to facilitate maintaining the composition within the nasal membrane for a period of time long enough to effectively moisturize the nasal membrane.
- a nasal moisturizer includes a gel and an encapsulated moisturizing agent.
- the gel includes purified water and glycerin.
- the moisturizing agent includes aloe barbadensis gel.
- the composition includes a thickener.
- the composition includes a nasal moisturizing agent encapsulated within lipid or liposomal vesicles.
- lipid or liposomal vesicles are formed of unilamellar vesicles or multilamellar vesicles.
- a method of treating a dry nasal membrane includes applying a nasal moisturizing composition to the nasal cavity using a nasal spray, aerosol or swab applicator.
- the present invention provides an improved composition for relieving symptoms of a dry nasal membrane and a method of using the same.
- the invention is conveniently described herein in terms of a high viscosity nasal moisturizing compound that can be easily applied through use of a nasal or aerosol spray, swab applicator or the like.
- the functional composition may be realized by any number of combinations of the ingredients listed below.
- the composition may vary in its viscosity level, which will allow the composition to be suitably configured for various intended applications.
- the nasal moisturizing composition of the present invention generally includes a carrier and one or more active ingredients dispersed within the carrier.
- the composition includes about 80-99.999 weight percent and preferable about 90-99.999 weight percent of a carrier.
- the carrier includes ingredients that are compatible with the nasal membrane and which form a composition having a viscosity high enough to maintain the composition in contact with the nasal membrane for an extended period of time.
- An exemplary carrier composition includes purified water, glycerin and a suitable thickening agent, and has a viscosity of about 2,500-40,000 centipoise and preferably about 5,000-20,000 centipoise, as measured using the Brookfield Syncho-Lectric Viscometer for the measurement of the apparent viscosity of newtonian and non-newtonian materials at low shear rates at given rotational speeds.
- the high viscosity carrier allows the composition to maintain contact with the nasal cavity without being drawn out by gravity or other forces which in turn allows active ingredient(s) within the carrier to remain proximate to or in contact with the nasal membrane.
- the composition includes about 95-97 weight percent purified water and about 0.75-1.25 weight percent glycerin which are mixed together to form a composition as discussed in more detail below, the composition may also include a thickener to further increase the viscosity of the composition.
- the active ingredients in the compositions of the present invention may be selected to perform a desired function.
- the active ingredients include agents that act to moisturize the nasal tissue without irritating the nasal cavity.
- the active ingredients may include, but are not limited to, moisturizing agents such as, glycerin, aloe barbadensis gel, tocopherol and the like.
- the composition includes about 0.001-2.0 weight percent active ingredient, and preferably about 0.002 to 1.25 weight percent.
- the composition may also include various optional ingredients such as additional thickeners, buffers, antibacterial agents and/or anti-microbial agents and/or preservatives to preserve and/or stabilize the formulations for manufacturing and storage.
- a buffer is used to maintain physiological pH.
- the composition may include any buffer that is capable of maintaining the desired pH.
- Exemplary buffers include, but are not limited to, sodium phosphate (monohydrate)/disodium phosphate (heptahydrate), sodium bicarbonate, and monobasic potassium phosphate/sodium hydroxide.
- a preservative maintains the sterility of the nasal moisturizer and may be used to extend the shelf life of the composition.
- Exemplary preservatives include, but are not limited to benzalkonium chloride, phenycarbinol and thimerosal.
- An antibacterial agent maintains the sterility of the composition and may also inhibit bacteria reproduction inside the nasal cavity.
- Exemplary antibacterial agents include, but are not limited to, hydrolyzed algin and chlorella vulgaris extract.
- An anti-microbial agent maintains the sterility of the composition, stabilizes the composition and may also kill pathogens inside the nasal cavity.
- Exemplary anti-microbial agents include, but are not limited to, chlorobutanol, sulfur dioxide, tetracycline, sorbic acid, ethanol, chlorohexidine, terconazole, nystatin, clotrimazole, and butoconazole.
- the nasal moisturizing composition may also include any one or more of additional pharmaceutical and/or cosmetic agents. These agents may facilitate the preservation of the composition.
- additional pharmaceutical and/or cosmetic agents include, for example, benzyl alcohol, disodium EDTA, hydroxylated lecithin, alkoylated diester, polysorbate 80, polysorbate 65, and procaine hydrochloride.
- One or more of the active ingredients may be encapsulated within lipid or liposomal vesicles to facilitate time-release dispersement of the active ingredients.
- This encapsulated composition allows for the active ingredient to be incorporated into the nasal tissue at a higher concentration than the active ingredient's water or lipid solubility, thereby allowing for increased absorption of the active ingredient into the nasal membrane.
- the nasal moisturizing composition includes a moisturizing agent.
- the moisturizing agent may be either a water soluble or lipid soluble composition that effectively moisturizes epithelial tissue.
- the moisturizing ingredient may also include a humectant.
- a humectant is a substance that promotes the retention and absorption of moisture from the air.
- Exemplary humectants include, but are not limited to glycerin, polyethylene glycol, polypropylene glycol, urea, sodium pyroglutamate, amino acids and the like.
- the humectant is glycerin.
- the nasal moisturizing composition includes purified water, one or more thickeners and a moisturizing agent.
- the purified water is the solvent for the composition and acts to maintain the composition's proper viscosity level.
- the thickeners operates to increase the viscosity level of the composition to a level high enough to maintain the composition in contact with the nasal membrane for a period of time long enough to moisturize the nasal tissue.
- the thickener may include, but is not limited to glycerin and hydroxyethylcelluose.
- the composition includes one or more active ingredients dispersed within the carrier.
- the active ingredients act to moisturize the nasal tissue without irritating the nasal cavity.
- the active moisturizing ingredients may include, but are not limited to moisturizing agents such as, glycerin, aloe barbadensis gel, tocopherol and the like.
- the moisturizing composition includes one or more time release active ingredients dispersed throughout the composition.
- the time release ingredient is encapsulated within lipid or liposomal vesicles.
- the lipid or liposomal vesicles are formed, for example, of unilamellar vesicles or multilamellar vesicles as described in U.S. Pat. No. 6,048,545.
- the moisturizing agents may include moisturizing agents such as, glycerin, aloe barbadensis gel, tocopherol and the like.
- each of the embodiments and each of the compositions are suitable for application to the nasal membrane using a swab applicator, a spray applicator or other device.
- the swab applicator is a device that fully encapsulates both the composition and the applicator.
- Each swab applicator device includes a desired amount of the composition, for example, approximately one ounce of composition and a sterile cotton swab applicator encased and sealed in a plastic tube. In this case each device has approximately enough composition for one application.
- the example provided below illustrates an exemplary nasal moisturizing compound of the present invention.
- the example is provided for illustration purposes only. This invention is not limited to the specific example provided herein.
- Weight Percent Components Range Exemplary Value Purified Water 95-100.00 95.522% Sodium Phosphate 1.500-3.000 1.5% Hydroxyethylcellulose 1.000-1.500 1.0% Disodium Phosphate 1.000-1.500 1.0% Glycerin 0.750-1.250 0.75% Alkoylated Diester 0.001-0.500 0.001% Aloe Barbadensis Gel 0.001-0.250 0.001% Hydrolyzed Algin 0.001-0.060 0.001% Chlorella Vulgaris Extract 0.001-0.060 0.001% Sea Water 0.001-1.000 0.001% Benzalkonium Chloride 0.010-0.100 0.01% Benzyl Alcohol 0.200-0.500 0.20% Disodium EDTA 0.010-0.100 0.01% Hydroxylated Lecithin 0.001-1.000 0.001%
- the solution is prepared by admixing the various components together.
Abstract
An improved composition and method for moisturizing a nasal membrane are disclosed. The composition includes a viscous carrier and one or more moisturizing agents disposed with the carrier. The composition is applied to a portion of a nasal membrane using a spray, a swab applicator, or a similar application device.
Description
- This application is a continuation-in-part of U.S. Pending patent application Ser. No. 09/388,816, entitled “METHOD AND COMPOSITION FOR DELIVERING ZINC TO THE NASAL MEMBRANE” and filed on Sep. 1, 1999, which is a continuation-in-part of U.S. patent application Ser. No. 09/145,042, entitled “METHOD AND COMPOSITION FOR DELIVERING ZINC TO THE NASAL MEMBRANE” and filed on Sep. 1, 1998; and is a continuation-in-part of U.S. Pending patent application Ser. No. 09/956,744, entitled “METHOD AND COMPOSITION FOR DELIVERING ZINC TO THE NASAL MEMBRANE” and filed on Sep. 12, 2001; which is a continuation of U.S. patent application Ser. No. 09/145,042, entitled “METHOD AND COMPOSITION FOR DELIVERING ZINC TO THE NASAL MEMBRANE” and filed on Sep. 1, 1998.
- The present invention generally relates to a method and composition for moisturizing nasal tissue.
- Compounds suitable for moisturizing a nasal cavity or a portion of a nasal cavity are desirable for several reasons. For example, application of a moisturizer to the nasal cavity may facilitate and/or promote healthy function of the cavity, which in turn may reduce the duration of symptoms associated with, for example, a common cold or the flu, and which may reduce the likelihood of an infection in the nasal region.
- In general, the nasal cavity performs several functions. The lower portion of the cavity includes the nasal epithelium, which is an essential part of the respiratory tract. The nasal epithelium is very vascular, which allows the epithelium to warm inspired air. The epithelium is also relatively moist, which allows it to moisten and cleanse inspired air. The cavity also includes a mucous membrane which lines the nasal cavity and traps fine particles such as dust, pollen and smoke.
- Nasal epithelial cells play an important role in warding of both bacteria and viruses. The cells act as a chemical, mechanical and microbiological barrier to infection. Typically, small glands within the nose secrete mucus, onto the nasal epithelial cells to moisten a portion of the nasal membrane. The cilia, hair like structures implanted in the epithelium and the immune system's first line of defense, are the cells responsible for trapping dust and bacteria. When the nasal membrane becomes dry, the cilia's movement slows and bacteria are better able to enter the respiratory system. To effectively function, the epithelial cells must generally be healthy and moist.
- Substances within air often act to irritate and dry out the nasal cavity. Sinusitis and allergens are two common conditions that affect the proper functioning of the nasal membrane. Sinusitis is an infection of any of the four groups of sinuses that prevents the proper drainage of mucous in the sinus passages. Sinusitis may stem from a cold or flu, allergies, pollution, injuries or various other conditions, which often result in a dry nasal passage.
- Inhaled allergens, including dust, pollen, molds, animal dander, and grass may react with the mucous membrane. This reaction may result in a drying or irritation of the nasal cavity. These factors along with dry climates, changing seasons, and pollution can all lead to nasal cavity dryness which may cause cracking and bleeding of the nose as well as various other acute or chronic conditions. Accordingly, methods and compositions for moisturizing a nasal membrane are desired.
- Presently, common treatment for nasal membrane dryness is either use of low-viscosity composition nasal sprays or use of a humidifier. Low-viscosity, over the counter nasal sprays generally remain in the nasal cavity only for a short period of time and therefore may be relatively ineffective at treating dry nasal cavities. A humidifier generally requires that the subject utilizing the humidifier remain proximate to the humidified air for a period of time and such use may therefore be problematic or undesirable in some instances. Accordingly, improved compositions, systems and methods for moisturizing the nasal membrane are desired.
- The present invention provides improved methods and compositions for moisturizing the nasal membrane.
- While the way in which the present invention addresses the disadvantages of the prior art will be discussed in greater detail below, in general, the present invention provides an effective nasal moisturizer that does not irritate nasal epithelium.
- In accordance with one exemplary embodiment of the present invention, the nasal moisturizer is a composition that includes an active moisturizing ingredient within a viscous gel. The gel has a viscosity in the range of 2,500 to 40,000 centipoise, preferably in the range of 5,000 to 20,000 centipoise. The active ingredient may include any number of materials appropriate for moisturizing nasal tissue. In accordance with one aspect of this embodiment of the invention, the nasal moisturizer is configured to facilitate maintaining the composition within the nasal membrane for a period of time long enough to effectively moisturize the nasal membrane.
- In accordance with another embodiment of the invention, a nasal moisturizer includes a gel and an encapsulated moisturizing agent. In accordance with one aspect of this embodiment, the gel includes purified water and glycerin. In accordance with another aspect of this embodiment of the invention, the moisturizing agent includesaloe barbadensis gel. In accordance with a further aspect of this embodiment, the composition includes a thickener.
- In accordance with another embodiment of the invention, the composition includes a nasal moisturizing agent encapsulated within lipid or liposomal vesicles. In accordance with various aspects of this embodiment, lipid or liposomal vesicles are formed of unilamellar vesicles or multilamellar vesicles.
- In accordance with another embodiment of the invention, a method of treating a dry nasal membrane includes applying a nasal moisturizing composition to the nasal cavity using a nasal spray, aerosol or swab applicator.
- The present invention provides an improved composition for relieving symptoms of a dry nasal membrane and a method of using the same. The invention is conveniently described herein in terms of a high viscosity nasal moisturizing compound that can be easily applied through use of a nasal or aerosol spray, swab applicator or the like. It should be appreciated that the functional composition may be realized by any number of combinations of the ingredients listed below. For example, the composition may vary in its viscosity level, which will allow the composition to be suitably configured for various intended applications.
- The nasal moisturizing composition of the present invention generally includes a carrier and one or more active ingredients dispersed within the carrier. In accordance with various embodiments of the invention, the composition includes about 80-99.999 weight percent and preferable about 90-99.999 weight percent of a carrier. The carrier includes ingredients that are compatible with the nasal membrane and which form a composition having a viscosity high enough to maintain the composition in contact with the nasal membrane for an extended period of time. An exemplary carrier composition includes purified water, glycerin and a suitable thickening agent, and has a viscosity of about 2,500-40,000 centipoise and preferably about 5,000-20,000 centipoise, as measured using the Brookfield Syncho-Lectric Viscometer for the measurement of the apparent viscosity of newtonian and non-newtonian materials at low shear rates at given rotational speeds. The high viscosity carrier allows the composition to maintain contact with the nasal cavity without being drawn out by gravity or other forces which in turn allows active ingredient(s) within the carrier to remain proximate to or in contact with the nasal membrane.
- In accordance with one exemplary embodiment of the invention the composition includes about 95-97 weight percent purified water and about 0.75-1.25 weight percent glycerin which are mixed together to form a composition as discussed in more detail below, the composition may also include a thickener to further increase the viscosity of the composition.
- The active ingredients in the compositions of the present invention may be selected to perform a desired function. In accordance with various embodiments of the invention, the active ingredients include agents that act to moisturize the nasal tissue without irritating the nasal cavity. The active ingredients may include, but are not limited to, moisturizing agents such as, glycerin,aloe barbadensis gel, tocopherol and the like. In accordance with one exemplary embodiment of the invention the composition includes about 0.001-2.0 weight percent active ingredient, and preferably about 0.002 to 1.25 weight percent.
- The composition may also include various optional ingredients such as additional thickeners, buffers, antibacterial agents and/or anti-microbial agents and/or preservatives to preserve and/or stabilize the formulations for manufacturing and storage. A buffer is used to maintain physiological pH. The composition may include any buffer that is capable of maintaining the desired pH. Exemplary buffers include, but are not limited to, sodium phosphate (monohydrate)/disodium phosphate (heptahydrate), sodium bicarbonate, and monobasic potassium phosphate/sodium hydroxide. A preservative maintains the sterility of the nasal moisturizer and may be used to extend the shelf life of the composition. Exemplary preservatives include, but are not limited to benzalkonium chloride, phenycarbinol and thimerosal. An antibacterial agent maintains the sterility of the composition and may also inhibit bacteria reproduction inside the nasal cavity. Exemplary antibacterial agents include, but are not limited to, hydrolyzed algin andchlorella vulgaris extract. An anti-microbial agent maintains the sterility of the composition, stabilizes the composition and may also kill pathogens inside the nasal cavity. Exemplary anti-microbial agents include, but are not limited to, chlorobutanol, sulfur dioxide, tetracycline, sorbic acid, ethanol, chlorohexidine, terconazole, nystatin, clotrimazole, and butoconazole.
- The nasal moisturizing composition may also include any one or more of additional pharmaceutical and/or cosmetic agents. These agents may facilitate the preservation of the composition. Exemplary pharmaceutical or cosmetic agents include, for example, benzyl alcohol, disodium EDTA, hydroxylated lecithin, alkoylated diester, polysorbate 80, polysorbate 65, and procaine hydrochloride.
- One or more of the active ingredients may be encapsulated within lipid or liposomal vesicles to facilitate time-release dispersement of the active ingredients. This encapsulated composition allows for the active ingredient to be incorporated into the nasal tissue at a higher concentration than the active ingredient's water or lipid solubility, thereby allowing for increased absorption of the active ingredient into the nasal membrane.
- As noted above, in accordance with various aspects of the invention, the nasal moisturizing composition includes a moisturizing agent. The moisturizing agent may be either a water soluble or lipid soluble composition that effectively moisturizes epithelial tissue. The moisturizing ingredient may also include a humectant. A humectant is a substance that promotes the retention and absorption of moisture from the air. Exemplary humectants include, but are not limited to glycerin, polyethylene glycol, polypropylene glycol, urea, sodium pyroglutamate, amino acids and the like. In accordance with one embodiment of the invention the humectant is glycerin.
- In accordance with an alternative embodiment of the invention, the nasal moisturizing composition includes purified water, one or more thickeners and a moisturizing agent. The purified water is the solvent for the composition and acts to maintain the composition's proper viscosity level. The thickeners operates to increase the viscosity level of the composition to a level high enough to maintain the composition in contact with the nasal membrane for a period of time long enough to moisturize the nasal tissue. The thickener may include, but is not limited to glycerin and hydroxyethylcelluose.
- In further accordance with this embodiment, the composition includes one or more active ingredients dispersed within the carrier. In accordance with various aspects of this embodiment, the active ingredients act to moisturize the nasal tissue without irritating the nasal cavity. The active moisturizing ingredients may include, but are not limited to moisturizing agents such as, glycerin,aloe barbadensis gel, tocopherol and the like.
- In accordance with another aspect of this exemplary embodiment of the invention, the moisturizing composition includes one or more time release active ingredients dispersed throughout the composition. In accordance with one aspect of the invention, the time release ingredient is encapsulated within lipid or liposomal vesicles. The lipid or liposomal vesicles are formed, for example, of unilamellar vesicles or multilamellar vesicles as described in U.S. Pat. No. 6,048,545. In accordance with another aspect of this embodiment, the moisturizing agents may include moisturizing agents such as, glycerin,aloe barbadensis gel, tocopherol and the like.
- Each of the embodiments and each of the compositions are suitable for application to the nasal membrane using a swab applicator, a spray applicator or other device. The swab applicator is a device that fully encapsulates both the composition and the applicator. Each swab applicator device includes a desired amount of the composition, for example, approximately one ounce of composition and a sterile cotton swab applicator encased and sealed in a plastic tube. In this case each device has approximately enough composition for one application.
- The example provided below illustrates an exemplary nasal moisturizing compound of the present invention. The example is provided for illustration purposes only. This invention is not limited to the specific example provided herein.
Weight Percent Components Range Exemplary Value Purified Water 95-100.00 95.522% Sodium Phosphate 1.500-3.000 1.5% Hydroxyethylcellulose 1.000-1.500 1.0% Disodium Phosphate 1.000-1.500 1.0% Glycerin 0.750-1.250 0.75% Alkoylated Diester 0.001-0.500 0.001% Aloe Barbadensis Gel 0.001-0.250 0.001% Hydrolyzed Algin 0.001-0.060 0.001% Chlorella Vulgaris Extract 0.001-0.060 0.001% Sea Water 0.001-1.000 0.001% Benzalkonium Chloride 0.010-0.100 0.01% Benzyl Alcohol 0.200-0.500 0.20% Disodium EDTA 0.010-0.100 0.01% Hydroxylated Lecithin 0.001-1.000 0.001% Tocopherol 0.001-0.100 0.001% Polysorbate 80 0.001-0.100 0.001% - The solution is prepared by admixing the various components together.
- The present invention has been described above with reference to exemplary embodiments. Those skilled in the art having read this disclosure will recognize that changes and modifications may be made to the embodiments without departing from the scope of the invention. For instance, the present invention has been described in connection with particular active moisturizing agents; however, various other active ingredients may suitably be used with the moisturizing compounds of the present invention. These and other changes or modifications are intended to be included within the scope of the present invention, as expressed in the following claims.
Claims (31)
1. A composition for moisturizing a nasal membrane comprising;
a gel having a viscosity greater than about 2,500 centipoise,
wherein said composition is configured to moisturize a nasal membrane.
2. The composition of claim 1 , wherein said composition comprises purified water and glycerin.
3. The composition of claim 2 , wherein said composition comprises about 80 to 99.999 weight percent purified water, and about 0.5 to about 1.5 weight percent glycerin.
4. The composition of claim 1 , wherein said composition further comprises a moisturizing agent selected from the group consisting of glycerin, aloe barbadensis gel, and tocopherol.
5. The composition of claim 1 further comprising a thickener.
6. The composition of claim 1 further comprising a material selected from the group consisting of an antibacterial agent and anti-microbial agent.
7. The composition of claim 6 , wherein said antibacterial agent comprises a material selected from the group consisting of chlorella vulgaris extract and hydrolyzed algin.
8. The composition of claim 1 , further comprising a buffer.
9. The composition of claim 8 , wherein said buffer comprises a material selected from the group consisting of sodium phosphate (monohydrate) and disodium phosphate (heptahydrate).
10. The composition of claim 1 , further comprising a preservative.
11. The composition of claim 1 , further comprising a material selected from the group consisting of benzalkonium chloride, disodium EDTA and benzyl alcohol.
12. The composition of claim 1 , further comprising a material selected from the group consisting of alkoylated diester, sea water, hydroxylated lecithin and polysorbate 80.
13. The composition of claim 1 , further comprising an encapsulate and an active ingredient within said encapsulate.
14. The composition of claim 13 , within said active ingredient comprises a moisturizing agent.
15. A composition for moisturizing a nasal membrane comprising;
purified water;
a hydrophilic thickener; and
a moisturizing agent.
16. The composition of claim 15 , wherein said composition comprises:
about 80 to 99.9999 weight percent purified water;
about 0.5 to 2.0 weight percent hydrophilic thickener; and
about 0.0001 to 2.25 weight percent moisturizing agent.
17. The composition of claim 16 , wherein said composition comprises:
about 90 to 99.999 weight percent purified water;
about 1.0 to 1.5 weight percent hydrophilic thickener;
about 0.001 to 1.0 weight percent moisturizing agent.
18. The composition of claim 15 , wherein said moisturizing agent comprises a humectant.
19. The composition of claim 15 , wherein said hydrophilic thickener comprises hydroxyethylcellulose.
20. The composition of claim 15 , wherein said moisturizing agent comprises a material selected from the group consisting of glycerin, aloe barbadensis gel, and tocopherol.
21. The composition of claim 15 , further comprising a material selected from the group of sodium phosphate (monohydrate), disodium phosphate (heptahydrate), hydrolyzed algin, chlorella vulgaris extract, alkoylated diester, sea water, disodium EDTA, hydroxylated lecithin, polysorbate 80, benzyl alcohol, and benzalkonium chloride.
22. A system for spraying the composition onto a portion of a nasal cavity comprising the composition of claim 15 .
23. A composition for moisturizing a nasal membrane comprising;
a gel;
a time-release moisturizing agent.
24. The composition of claim 23 , wherein said time-release agent is encapsulated in a liposomal agent.
25. The composition of claim 23 , wherein said moisturizing agent comprises a material selected from the group consisting of glycerin, aloe barbadensis gel, and tocopherol.
26. The composition of claim 23 , further comprising a material selected from the group consisting of an antibacterial agent and an anti-microbial agent.
27. The composition of claim 26 , wherein said antibacterial agent comprises a material selected from the group consisting of chlorella vulgaris extract and hydrolyzed algin.
28. The composition of claim 23 , wherein said composition comprises a material selected from the group consisting of sodium phosphate (monohydrate), disodium phosphate (heptahydrate), hydroxyethylcellulose, alkoylated diester, sea water, disodium EDTA, hydroxylated lecithin, polysorbate 80, benzyl alcohol, and benzalkonium chloride.
29. A method of moisturizing a nasal membrane, the method comprising the steps of:
providing a composition having a viscosity greater than about 2,500 centipoise;
applying the composition to the nasal membrane in an amount effective to moisturize the nasal membrane; and
maintaining the composition in contact with the nasal membrane for a time period sufficient to moisturize the contacted nasal membrane cells.
30. The method of claim 29 , wherein said applying step comprises applying the composition with a cotton swab.
31. The method of claim 29 , wherein said applying step comprises applying the composition with a nasal spray.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/243,637 US20030059440A1 (en) | 1998-09-01 | 2002-09-13 | Composition and method for moisturizing nasal tissue |
AU2003278806A AU2003278806A1 (en) | 2002-09-13 | 2003-09-12 | Composition and method for moisturizing nasal tissue |
PCT/US2003/028780 WO2004024122A1 (en) | 2002-09-13 | 2003-09-12 | Composition and method for moisturizing nasal tissue |
US11/109,128 US7439269B2 (en) | 1998-09-01 | 2005-04-18 | Composition and method for moisturizing nasal tissue |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/145,042 US6080783A (en) | 1998-09-01 | 1998-09-01 | Method and composition for delivering zinc to the nasal membrane |
US09/388,816 US6673835B1 (en) | 1998-09-01 | 1999-09-01 | Method and composition for delivering zinc to the nasal membrane |
US10/243,637 US20030059440A1 (en) | 1998-09-01 | 2002-09-13 | Composition and method for moisturizing nasal tissue |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/388,816 Continuation-In-Part US6673835B1 (en) | 1998-09-01 | 1999-09-01 | Method and composition for delivering zinc to the nasal membrane |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/109,128 Division US7439269B2 (en) | 1998-09-01 | 2005-04-18 | Composition and method for moisturizing nasal tissue |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030059440A1 true US20030059440A1 (en) | 2003-03-27 |
Family
ID=31991701
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/243,637 Abandoned US20030059440A1 (en) | 1998-09-01 | 2002-09-13 | Composition and method for moisturizing nasal tissue |
US11/109,128 Expired - Fee Related US7439269B2 (en) | 1998-09-01 | 2005-04-18 | Composition and method for moisturizing nasal tissue |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/109,128 Expired - Fee Related US7439269B2 (en) | 1998-09-01 | 2005-04-18 | Composition and method for moisturizing nasal tissue |
Country Status (3)
Country | Link |
---|---|
US (2) | US20030059440A1 (en) |
AU (1) | AU2003278806A1 (en) |
WO (1) | WO2004024122A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030220485A1 (en) * | 1998-05-13 | 2003-11-27 | Carrington Laboratories, Inc. | High molecular weight, low methoxyl pectins, and their production and uses |
US20070111964A1 (en) * | 2005-08-17 | 2007-05-17 | Fleming And Company, Pharmaceuticals | Vitamin B12 nasal spray and method of use |
US20080026078A1 (en) * | 2006-07-25 | 2008-01-31 | Zinreich James | Nasal composition |
US20080069897A1 (en) * | 2006-08-01 | 2008-03-20 | Tim Clarot | Method for promoting and maintaining respiratory tract health |
US20110086114A1 (en) * | 2006-07-25 | 2011-04-14 | Zinreich James | Nasal composition |
US20110275587A1 (en) * | 2010-04-27 | 2011-11-10 | Reitz Russell N | Topical delivery of viscous medications for the treatment of diseases associated with chronic sinusitis |
US8173183B2 (en) | 2008-07-02 | 2012-05-08 | Carmell Hergert | Mucosal membrane healant and moisturizer |
US20160193270A1 (en) * | 2004-09-07 | 2016-07-07 | 3M Innovative Properties Company | Antiseptic compositons and methods of use |
DE102019129085A1 (en) * | 2019-10-23 | 2021-04-29 | AXPHARM Sp. Z O.o. | Preparation for the regeneration and moistening of the nasal mucosa |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003266159A1 (en) * | 2002-09-16 | 2004-04-30 | Zicam, Llc. | System and method for delivering a composition to the nasal membrane |
FR2900576B1 (en) * | 2006-05-03 | 2008-09-19 | Centre Nat Rech Scient | PROCESS FOR EXTEMPORANEOUS AND REVERSIBLE CONCENTRATION OF LIPOSOMES. |
US20100147300A1 (en) * | 2008-12-17 | 2010-06-17 | Clickmist, A Series Of The Invention Machine, Llc | Nasal humidification and dispensing device |
US8524290B2 (en) | 2010-10-20 | 2013-09-03 | John E. Kulesza | Non-occluding nasal moisturizer and methods of use |
FR2971713B1 (en) * | 2011-02-18 | 2019-03-29 | Laboratoire De La Mer | AQUEOUS IONIC SOLUTION CONTAINING SEA WATER AND AT LEAST ONE COMPOUND ORIGINALLY UNMISCIBLE TO SEA WATER. |
US8877259B2 (en) | 2012-02-09 | 2014-11-04 | Mary Kay Inc. | Cosmetic formulation |
KR102053487B1 (en) * | 2013-03-15 | 2019-12-06 | 아이리스 인터내셔널 인크. | Sheath fluid systems and methods for particle analysis in blood samples |
CN105102959B (en) | 2013-03-15 | 2017-06-09 | 艾瑞思国际股份有限公司 | For the flow cell system and method for the grading analysis in blood sample |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4885287A (en) * | 1988-08-09 | 1989-12-05 | University Of Kentucky Research Foundation | Novel method of administering aspirin and dosage forms containing same |
US5419898A (en) * | 1992-12-25 | 1995-05-30 | Senju Pharmacuetical Co., Ltd. | Antiallergic composition for ophthalmic or nasal use |
US5897872A (en) * | 1997-11-12 | 1999-04-27 | Picciano; Dante J. | Iodine-containing nasal moisturizing saline solution |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3146570A1 (en) * | 1980-12-06 | 1982-07-08 | Dr.med. Dietrich Ibiza Reichert | Composition for controlling snoring |
CA2045469A1 (en) * | 1989-02-17 | 1990-08-18 | Alan L. Weiner | Lipid excipient for nasal delivery and topical application |
GB9103824D0 (en) * | 1991-02-23 | 1991-04-10 | Fisons Ag | Formulation |
IL101056A (en) * | 1992-02-24 | 1997-03-18 | Res & Dev Co Ltd | Composition for nasal treatment |
US5993850A (en) * | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
NZ505919A (en) * | 1998-01-30 | 2002-10-25 | Novartis Consumer Health S | Nasal solutions |
AU4594601A (en) * | 2000-03-23 | 2001-10-03 | Collaborative Technologies Inc | Base compositions for preparing surfactant free topical compositions |
-
2002
- 2002-09-13 US US10/243,637 patent/US20030059440A1/en not_active Abandoned
-
2003
- 2003-09-12 WO PCT/US2003/028780 patent/WO2004024122A1/en not_active Application Discontinuation
- 2003-09-12 AU AU2003278806A patent/AU2003278806A1/en not_active Abandoned
-
2005
- 2005-04-18 US US11/109,128 patent/US7439269B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4885287A (en) * | 1988-08-09 | 1989-12-05 | University Of Kentucky Research Foundation | Novel method of administering aspirin and dosage forms containing same |
US5419898A (en) * | 1992-12-25 | 1995-05-30 | Senju Pharmacuetical Co., Ltd. | Antiallergic composition for ophthalmic or nasal use |
US5897872A (en) * | 1997-11-12 | 1999-04-27 | Picciano; Dante J. | Iodine-containing nasal moisturizing saline solution |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7705135B2 (en) | 1998-05-13 | 2010-04-27 | Nanotherapeutics, Inc. | Pharmaceutical compositions comprising aloe pectins, and methods for their production and use |
US20030220485A1 (en) * | 1998-05-13 | 2003-11-27 | Carrington Laboratories, Inc. | High molecular weight, low methoxyl pectins, and their production and uses |
US7691986B2 (en) | 1998-05-13 | 2010-04-06 | Nanotherapeutics, Inc. | High molecular weight, low methoxyl pectins, and their production and uses |
US20160193270A1 (en) * | 2004-09-07 | 2016-07-07 | 3M Innovative Properties Company | Antiseptic compositons and methods of use |
US20070111964A1 (en) * | 2005-08-17 | 2007-05-17 | Fleming And Company, Pharmaceuticals | Vitamin B12 nasal spray and method of use |
US8337906B2 (en) | 2006-07-25 | 2012-12-25 | Zinreich James | Nasal composition |
US20110086114A1 (en) * | 2006-07-25 | 2011-04-14 | Zinreich James | Nasal composition |
US20080026078A1 (en) * | 2006-07-25 | 2008-01-31 | Zinreich James | Nasal composition |
US20080069897A1 (en) * | 2006-08-01 | 2008-03-20 | Tim Clarot | Method for promoting and maintaining respiratory tract health |
US8173183B2 (en) | 2008-07-02 | 2012-05-08 | Carmell Hergert | Mucosal membrane healant and moisturizer |
US20110275587A1 (en) * | 2010-04-27 | 2011-11-10 | Reitz Russell N | Topical delivery of viscous medications for the treatment of diseases associated with chronic sinusitis |
US8916171B2 (en) * | 2010-04-27 | 2014-12-23 | Topical Sinus Therapeutics, Inc. | Topical delivery of viscous medications for the treatment of diseases associated with chronic sinusitis |
DE102019129085A1 (en) * | 2019-10-23 | 2021-04-29 | AXPHARM Sp. Z O.o. | Preparation for the regeneration and moistening of the nasal mucosa |
Also Published As
Publication number | Publication date |
---|---|
WO2004024122A1 (en) | 2004-03-25 |
AU2003278806A1 (en) | 2004-04-30 |
US7439269B2 (en) | 2008-10-21 |
US20050180924A1 (en) | 2005-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7439269B2 (en) | Composition and method for moisturizing nasal tissue | |
US5897858A (en) | Nasal spray compositions exhibiting increased retention in the nasal cavity | |
ES2244831T3 (en) | PHARMACEUTICAL COMPOSITION FOR OPHTHALMOLOGICAL AND RHINOLOGICAL APPLICATION. | |
US5897872A (en) | Iodine-containing nasal moisturizing saline solution | |
US7348360B2 (en) | Method and composition for delivering zinc to the nasal membrane | |
US7597901B2 (en) | System for delivering a composition to the nasal membrane and method of using the same | |
US6342537B1 (en) | Gel for treatment of skin diseases and for disinfection of the skin | |
US6171611B1 (en) | Iodine-containing nasal moisturizing saline and mouthwash solutions | |
JPH0161086B2 (en) | ||
US10813889B2 (en) | Cannabinoid and menthol compositions and methods | |
HUE027474T2 (en) | Nasal spray | |
ES2860098T3 (en) | Composition for nasal application | |
WO2006066500A1 (en) | The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease | |
CA2347301A1 (en) | Proanthocyanidins and ascorbic acid composition for topical application to human respiratory and oral mucosa | |
US8940319B2 (en) | Formulations, devices and methods for treating and preventing mucositis | |
US20040122110A1 (en) | Effect of vitamin A gel on paranasal sinus mucosal regeneration | |
JPH10130148A (en) | Composition for nebulizer | |
CA2141645A1 (en) | Nasal spray compositions | |
US20080026078A1 (en) | Nasal composition | |
EP1108422A2 (en) | Medical product for moisturising and cleansing the nasal mucosa | |
WO2021177937A1 (en) | Cannabinoid and menthol compositions and methods | |
CN116712354A (en) | Gel liquid for removing tear marks of pets | |
MXPA00005047A (en) | Method and composition for delivering zinc to the nasal membrane |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MATRIXX INITIATIVES, INC., ARIZONA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CLAROT, TIM;HENSLEY, CHARLES;REEL/FRAME:015880/0117 Effective date: 20041004 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |